All the news Showing 10 of 58 articles from: Disease course and symptomsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Liver cancer risk will remain elevated for people with cirrhosis cured of hepatitis C Keith Alcorn / 16 November 2015 The burden of liver cancer and cirrhosis caused by hepatitis C is likely to continue to grow in the United States despite curative treatment for hepatitis C, and people who have cirrhosis ... Hepatitis B patients on long-term entecavir or tenofovir have low mortality, but liver cancer remains a risk Liz Highleyman / 03 June 2015 More than 95% of people with chronic hepatitis B were still alive after five years on antiviral therapy with entecavir (Baraclude) or tenofovir (Viread) and most deaths were due to non-liver-related causes, according ... Statin use associated with lower risk of liver decompensation and death in hepatitis C patients with cirrhosis Liz Highleyman / 19 May 2015 People with hepatitis and liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood cholesterol, according to an analysis of ... Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants Liz Highleyman / 29 April 2015 An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response rates of 83% for people with hepatitis C virus (HCV) who had advanced liver cirrhosis and 94% for ... Alcohol misuse the strongest predictor of severe liver damage and death in French people with hepatitis C Keith Alcorn / 28 April 2015 People with hepatitis C have a much greater risk of liver-related hospitalisation or death if they have an alcohol use disorder or another serious co-morbidity such as HIV infection, chronic kidney disease ... Deferring hepatitis C treatment can lead to liver cancer and death, despite cure Liz Highleyman / 05 March 2015 People with HIV and hepatitis C co-infection who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being cured – with outcomes worsening the ... Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis Liz Highleyman / 12 November 2014 An oral regimen of sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation ... Hepatitis B treatment with entecavir or tenofovir lowers, but does not eliminate, liver cancer risk Liz Highleyman / 11 November 2013 Long-term treatment with entecavir can reduce the likelihood that people with chronic hepatitis B will develop hepatocellular carcinoma, according to findings presented last week at The Liver Meeting 2013, the 64th annual meeting ... New-onset diabetes accelerates the pace of liver disease in people with chronic HBV Michael Carter / 02 October 2013 New-onset diabetes is associated with the development of liver cirrhosis and decompensated cirrhosis in people with chronic hepatitis B virus (HBV) infection, according to the results of a study published in the online ... Decompensated cirrhosis increases risk of liver cancer for people with HIV and viral hepatitis co-infection Michael Carter / 10 September 2013 There is a relatively low incidence of hepatocellular carcinoma (HCC) among people living with HIV who have liver cirrhosis, results of a prospective Spanish study published in the online edition of the ... ← Prev1...23456Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV New and experimental therapies Hepatitis C Hepatitis D Hepatitis E NAFLD Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds